| Rank |
Title |
Year |
PubWeight™‹?› |
|
1
|
The regulation of inflammation by interferons and their STATs.
|
2013
|
1.35
|
|
2
|
STAT1 and STAT3 in tumorigenesis: A matter of balance.
|
2012
|
1.27
|
|
3
|
STAT3 and epithelial-mesenchymal transitions in carcinomas.
|
2014
|
1.24
|
|
4
|
Targeting the tumor microenvironment: JAK-STAT3 signaling.
|
2013
|
1.14
|
|
5
|
SOCS, inflammation, and cancer.
|
2013
|
1.13
|
|
6
|
The role of JAK-STAT signaling within the CNS.
|
2013
|
1.12
|
|
7
|
STATs get their move on.
|
2013
|
1.08
|
|
8
|
Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity.
|
2013
|
1.04
|
|
9
|
STAT3 activation: A key factor in tumor immunoescape.
|
2013
|
1.04
|
|
10
|
Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway.
|
2013
|
1.04
|
|
11
|
STAT3 signaling in pulmonary arterial hypertension.
|
2012
|
1.04
|
|
12
|
The involvement of JAK-STAT3 in cell motility, invasion, and metastasis.
|
2014
|
1.03
|
|
13
|
Nucleic acid-based approaches to STAT inhibition.
|
2012
|
1.02
|
|
14
|
STAT2 and IRF9: Beyond ISGF3.
|
2013
|
1.01
|
|
15
|
The tumor suppressor function of STAT1 in breast cancer.
|
2013
|
1.00
|
|
16
|
Alternative ways of modulating JAK-STAT pathway: Looking beyond phosphorylation.
|
2012
|
0.99
|
|
17
|
The consequences of selective inhibition of signal transducer and activator of transcription 3 (STAT3) tyrosine705 phosphorylation by phosphopeptide mimetic prodrugs targeting the Src homology 2 (SH2) domain.
|
2012
|
0.98
|
|
18
|
Interleukin-2 and STAT5 in regulatory T cell development and function.
|
2013
|
0.98
|
|
19
|
Screening approaches to generating STAT inhibitors: Allowing the hits to identify the targets.
|
2012
|
0.98
|
|
20
|
PKM2, STAT3 and HIF-1α: The Warburg's vicious circle.
|
2012
|
0.96
|
|
21
|
STAT3 inhibitors for cancer therapy: Have all roads been explored?
|
2013
|
0.94
|
|
22
|
STAT3 and the Hyper-IgE syndrome: Clinical presentation, genetic origin, pathogenesis, novel findings and remaining uncertainties.
|
2013
|
0.94
|
|
23
|
IL-6-STAT3 signaling and premature senescence.
|
2013
|
0.93
|
|
24
|
How should we define STAT3 as an oncogene and as a potential target for therapy?
|
2013
|
0.93
|
|
25
|
Changing partners at the dance: Variations in STAT concentrations for shaping cytokine function and immune responses to viral infections.
|
2013
|
0.92
|
|
26
|
STAT signaling in the pathogenesis and treatment of myeloid malignancies.
|
2012
|
0.92
|
|
27
|
STAT6 and lung inflammation.
|
2013
|
0.92
|
|
28
|
The Drosophila JAK-STAT pathway in blood cell formation and immunity.
|
2013
|
0.91
|
|
29
|
JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms.
|
2013
|
0.91
|
|
30
|
Regulation of STATs by polycystin-1 and their role in polycystic kidney disease.
|
2013
|
0.91
|
|
31
|
STAT5 in hematopoietic stem cell biology and transplantation.
|
2013
|
0.90
|
|
32
|
The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis.
|
2013
|
0.90
|
|
33
|
Therapeutic targeting of STAT pathways in CNS autoimmune diseases.
|
2013
|
0.90
|
|
34
|
JAK-STAT and bone metabolism.
|
2013
|
0.90
|
|
35
|
JAK-STAT and intestinal mucosal immunology.
|
2013
|
0.89
|
|
36
|
Non-genomic STAT5-dependent effects at the endoplasmic reticulum and Golgi apparatus and STAT6-GFP in mitochondria.
|
2013
|
0.89
|
|
37
|
STAT heterodimers in immunity: A mixed message or a unique signal?
|
2013
|
0.89
|
|
38
|
JAK-STAT3 and somatic cell reprogramming.
|
2013
|
0.88
|
|
39
|
STAT3 regulation of and by microRNAs in development and disease.
|
2012
|
0.88
|
|
40
|
Regulation of proliferation, cell competition, and cellular growth by the Drosophila JAK-STAT pathway.
|
2013
|
0.88
|
|
41
|
Infection-induced IL-10 and JAK-STAT: A review of the molecular circuitry controlling immune hyperactivity in response to pathogenic microbes.
|
2012
|
0.88
|
|
42
|
STAT transcription in the ischemic heart.
|
2012
|
0.87
|
|
43
|
Evolution of the JAK-STAT pathway.
|
2013
|
0.86
|
|
44
|
STAT2: A shape-shifting anti-viral super STAT.
|
2013
|
0.86
|
|
45
|
Comparative evolutionary genomics of the STAT family of transcription factors.
|
2012
|
0.86
|
|
46
|
SOCS3: An essential physiological inhibitor of signaling by interleukin-6 and G-CSF family cytokines.
|
2013
|
0.86
|
|
47
|
Differential STAT3 signaling in the heart: Impact of concurrent signals and oxidative stress.
|
2012
|
0.85
|
|
48
|
Cytokine signaling in the differentiation of innate effector cells.
|
2013
|
0.85
|
|
49
|
Determinants of the extent and duration of STAT3 signaling.
|
2012
|
0.85
|
|
50
|
Wheezing and itching: The requirement for STAT proteins in allergic inflammation.
|
2012
|
0.84
|